Td Private Client Wealth LLC Halozyme Therapeutics, Inc. Transaction History
Td Private Client Wealth LLC
- $4.07 Trillion
- Q2 2025
A detailed history of Td Private Client Wealth LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Td Private Client Wealth LLC holds 52 shares of HALO stock, worth $3,070. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52
Previous 76
31.58%
Holding current value
$3,070
Previous $4.85 Million
44.23%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
585Shares Held
122MCall Options Held
308KPut Options Held
131K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$758 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$357 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$230 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$217 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.23B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...